Granules India rises on getting USFDA`s approval for Venlafaxine Hydrochloride Capsules
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Granules India is currently trading at Rs. 278.85, up by 1.20 points or 0.43% from its previous closing of Rs. 277.65 on the BSE.
The scrip opened at Rs. 278.70 and has touched a high and low of Rs. 283.00 and Rs. 274.25 respectively. So far 26185 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 381.25 on 04-Nov-2022 and a 52 week low of Rs. 227.00 on 20-Jun-2022.
Last one week high and low of the scrip stood at Rs. 302.25 and Rs. 274.25 respectively. The current market cap of the company is Rs. 6670.70 crore.
The promoters holding in the company stood at 42.02%, while Institutions and Non-Institutions held 28.93% and 29.05% respectively.
Granules India has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Venlafaxine Hydrochloride Extended-Release Capsules USP, 37.5 mg, 75 mg, and 150 mg. It is bioequivalent to the reference listed drug product (RLD), Effexor XR Extended-Release Capsules of Upjohn US 2 LLC.
Venlafaxine HCI extended-release capsules are indicated for the treatment of: Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD) and Panic Disorder (PD) Granules now have a total of 56 ANDA approvals from US FDA (54 Final approvals and 2 tentative approvals). The current annual U.S. market for Venlafaxine ER Capsules is approximately $153 Million, according to MAT Mar 2023, IQVIA/IMS Health.
Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).
